Comparative efficacy and safety of the trastuzumab biosimilar HLX02 versus originator trastuzumab in the neoadjuvant THP-EC regimen for early-stage HER2-positive breast cancer: a real-world study [0.03%]
赫赛汀原研药与汉曲优生物类似物用于新辅助THP-EC方案治疗早期HER2阳性乳腺癌的疗效和安全性比较：真实世界研究
Mingyu Wang,Xingye Sheng,Qiannan Zhu et al.
Mingyu Wang et al.
Objectives: HER2-positive breast cancer is an aggressive subtype. High-cost originator trastuzumab limits treatment access, making biosimilars like HLX02 a valuable alternative. ...
Extracellular RNAs in pancreatic cancer: from pathogenesis to precision medicine [0.03%]
胰腺癌中的细胞外RNA：从发病机制到精准医学
Mohammad Rezazadeh,Ava Aghakhani,Farbod Bahreini et al.
Mohammad Rezazadeh et al.
Introduction: Pancreatic cancer is highly aggressive with poor prognosis and limited therapies. Extracellular RNAs (exRNAs), including microRNAs (miRNAs), long noncoding RNAs (lncRNAs), and circular RNAs (circRNAs), play ...
An evaluation of axatilimab for the treatment of chronic graft-versus-host disease [0.03%]
AXA195（axatilimab）治疗慢性移植物抗宿主病疗效的评估分析
Saurabh Chhabra,Sriram Banigallapati
Saurabh Chhabra
Introduction: Chronic graft-versus-host disease (cGVHD), a frequent, debilitating autoimmune-like syndrome affecting allogeneic transplant recipients begins with inflammatory response to per-transplant tissue injury which...
A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM) [0.03%]
单克隆抗体为基础的疗法治疗复发/难治多发性骨髓瘤(RRMM)的临床疗效综述
Yuxin Liu,Ji Hyun Lee,Clifton C Mo et al.
Yuxin Liu et al.
Introduction: Monoclonal antibodies (mAbs) and antibody - drug conjugates (ADCs) are among the backbones of treatment for relapsed/refractory multiple myeloma (RRMM). Beyond current standard-of-care regimens, the roles of...
What does the future hold for antibody-drug conjugate therapies in ovarian cancer? [0.03%]
抗体偶联药物治疗卵巢癌的未来展望？
Page C Widick,Ursula A Matulonis,Meghan Shea
Page C Widick
When adalimumab fails in childhood chronic uveitis: what comes next? [0.03%]
当儿童慢性葡萄膜炎对阿达木单抗治疗无效时，下一步该如何？
Ilaria Maccora,Gabriele Simonini
Ilaria Maccora
Nivolumab plus ipilimumab for hepatocellular carcinoma: a game-changer? [0.03%]
尼伏单抗联合伊匹木单抗治疗肝细胞癌：一场变革？
Lorenza Di Marco,Federica Valerio,Yuri Maculan et al.
Lorenza Di Marco et al.
Introduction: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, largely arising in the setting of chronic liver disease and cirrhosis. Given the immunosuppressive hepatic tumor ...
Alessio Aloisio,Chiara Baldovini,Olivier Thaunat et al.
Alessio Aloisio et al.
Introduction: Antibody-mediated rejection (AMR) is a major obstacle after heart transplantation. Although its pathophysiology is now clearer than a decade ago, clinical management is still fragmented and poorly evidence-b...
Current outlook on the use of monoclonal antibody therapies for osteoporosis [0.03%]
抗RANKL单克隆抗体治疗骨质疏松症的现状及展望
Mohammed Almohaya,Mohammed Almehthel,David Kendler
Mohammed Almohaya
Introduction: The availability of monoclonal antibody therapies impacting on the basic pathways of bone formation ;(romosozumab) and bone resorption (denosumab) has contributed greatly to our ability to manage patients wi...
An evaluation of prademagene zamikeracel for the treatment of recessive dystrophic epidermolysis bullosa [0.03%]
PradeMagene Zamikeracel治疗营养不良型交界性大疱性表皮松解症的效果评估研究
Aleksandra Lesiak,M Peter Marinkovich
Aleksandra Lesiak
Introduction: Prademagene zamikeracel is an autologous, genetically corrected epidermal graft therapy designed to address the underlying molecular defect in recessive dystrophic epidermolysis bullosa (RDEB). The product i...